Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
4.370
+0.060 (1.39%)
At close: Apr 2, 2026, 4:00 PM EDT
4.450
+0.080 (1.83%)
After-hours: Apr 2, 2026, 7:49 PM EDT
Taysha Gene Therapies Stock Forecast
Stock Price Forecast
The 9 analysts that cover Taysha Gene Therapies stock have a consensus rating of "Strong Buy" and an average price target of $10.78, which forecasts a 146.68% increase in the stock price over the next year. The lowest target is $7.00 and the highest is $14.
Price Target: $10.78 (+146.68%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Taysha Gene Therapies stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Maintains $10 → $12 | Strong Buy | Maintains | $10 → $12 | +174.60% | Mar 19, 2026 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $12 | Strong Buy | Maintains | $12 | +174.60% | Mar 19, 2026 |
| Needham | Needham | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +128.83% | Mar 3, 2026 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $12 | Strong Buy | Maintains | $12 | +174.60% | Jan 6, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $8 → $11 | Buy | Maintains | $8 → $11 | +151.72% | Jan 5, 2026 |
Financial Forecast
Revenue This Year
3.86M
from 9.77M
Decreased by -60.47%
Revenue Next Year
51.32M
from 3.86M
Increased by 1,228.40%
EPS This Year
-0.44
from -0.34
EPS Next Year
-0.53
from -0.44
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 15.8M | 121.5M | |||
| Avg | 3.9M | 51.3M | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 61.2% | 3,046.0% | |||
| Avg | -60.5% | 1,228.4% | |||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.37 | -0.40 | |||
| Avg | -0.44 | -0.53 | |||
| Low | -0.53 | -0.60 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.